Compare Expensify Inc (EXFY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Revvity Inc — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 81.3× Expensify Inc's market cap, and Revvity Inc pays a 0.18% dividend while Expensify Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Revvity Inc for 12 Days on average.
| EXFY | RVTY | |
|---|---|---|
Market Cap | $208.82M | $16.98B |
Volume | 456,102 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $2.72 | $157.36 |
52-Week Low | $0.75 | $82.26 |
Typical Hold Time | 41 Days | 12 Days |
Enterprise Value | $148.44M | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.40, up 5.73% today, showing technical bullish momentum with positive moving averages. The company reported mixed quarterly results with recent beats but maintains negative profitability metrics. Recent business developments include strategic AI integrations and European expansion of its corporate card program, signaling growth initiatives despite ongoing net losses.
The outlook remains speculative with analyst consensus pointing to significant upside potential ($13.75 target) but fundamental challenges persist including negative margins and cash flow volatility. Key risks include execution on AI transition and competitive pressure in expense management software, while institutional sentiment leans bullish with 50% buy ratings.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
